Publications Repository

Publications Repository

View item 
  •   Home
  • ICR Divisions
  • Cancer Therapeutics
  • View item
  • Home
  • ICR Divisions
  • Cancer Therapeutics
  • View item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Targeting <i>BRAF</i>-Mutant Colorectal Cancer: Progress in Combination Strategies.

Thumbnail
View/Open
Supporting information (63.31Kb)
Date
2017-06
ICR Author
Yap, Timothy
Marsden,
Author
Sundar, R
Hong, DS
Kopetz, S
Yap, TA
Type
Journal Article
Metadata
Show full item record
Abstract
BRAF mutations in colorectal cancer portend a poor prognosis, with first-line treatment often involving triplet or quadruplet chemotherapy, and single-agent targeted therapy with BRAF inhibitors failing to demonstrate clinical activity. Blockade of multiple critical nodes along the MAPK and other pathways may be necessary to improve response rates and survival. Cancer Discov; 7(6); 558-60. © 2017 AACR. See related article by van Geel et al., p. 610 .
URI
https://repository.icr.ac.uk/handle/internal/1266
DOI
https://doi.org/10.1158/2159-8290.cd-17-0087
Collections
  • Cancer Therapeutics
  • Clinical Studies
Subject
Animals
Humans
Colorectal Neoplasms
Proto-Oncogene Proteins B-raf
Mitogen-Activated Protein Kinases
Antineoplastic Combined Chemotherapy Protocols
Mutation
Molecular Targeted Therapy
Research team
Medicine Drug Development Unit (de Bono)
Language
eng
License start date
2017-06
Citation
Cancer discovery, 2017, 7 (6), pp. 558 - 560

Browse

All of ICR repositoryICR DivisionsBy issue dateAuthorsTitlesPublication TypesThis collectionBy issue dateAuthorsTitlesPublication Types
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.